Literature DB >> 16520158

Reduced lung function in patients with abdominal aortic aneurysm is associated with activation of inflammation and hemostasis, not smoking or cardiovascular disease.

F Gerald R Fowkes1, Chantelle L C Anandan, Amanda J Lee, Felicity B Smith, Ioanna Tzoulaki, Ann Rumley, Janet T Powell, Gordon D O Lowe.   

Abstract

OBJECTIVE: Abdominal aortic aneurysms often coexist with reduced lung function and chronic obstructive pulmonary disease (COPD). These conditions are each associated with cigarette smoking, cardiovascular disease, and evidence of increased inflammatory and hemostatic activity. The aim of this study was to determine if these factors accounted for the link between aneurysms and pulmonary disease.
METHODS: The design was a case-control study comparing patients with an asymptomatic abdominal aortic aneurysm with population-based controls without an aneurysm. Aneurysms were diagnosed by ultrasound scan, and pulmonary function was measured by respiratory questionnaire and spirometry. Activation of inflammation and hemostasis was measured by assay of plasma interleukin-6 (IL-6), fibrinogen, von Willebrand factor (vWF), tissue plasminogen activator (tPA) antigen, fibrin D-dimer, and plasmin antiplasmin complexes.
RESULTS: Cases with an abdominal aortic aneurysm (n = 89) had more COPD and worse expiratory lung function as measured by forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) than controls (n = 98) (FEV1, 1.9 vs 2.2 L, P < .01; FEV1/FVC, 0.67 vs 0.75, P < .001) and did not differ in restrictive function (FVC, 2.9 vs 3.0 L, P = .33). Cases also had higher levels of lifetime cigarette smoking (30 vs 24 pack-years, P < 0.01), cardiovascular disease (35% vs 18%, P = .01), plasma fibrinogen (3.5 vs 3.1 g/L, P = .02), IL-6 (2.8 vs 1.8, pg/mL, P < .001), plasmin antiplasmin complexes (596 vs 384 microg/L, P = .01), and D-dimer (442 vs 93 ng/mL, P < .001). On multiple logistic regression analysis of lung function and COPD on the risk of aneurysm, both cigarette smoking and cardiovascular disease had little effect on the relationships. For the markers of activated inflammation and hemostasis, plasmin antiplasmin complexes and D-dimer had the most important confounding effect on the odds ratios. All markers combined had a substantial effect: odds ratio of aneurysm for a one standard deviation decrease in FEV1 fell from 2.3 (95% confidence interval [CI], 1.5 to 3.5) (P < .01) to 1.3 (95% CI, 0.55 to 2.4) (P > or = .05).
CONCLUSION: The association between reduced respiratory function and abdominal aortic aneurysm was not accounted for by cigarette smoking or cardiovascular disease. We hypothesize that activation of inflammation and hemostasis in response to injury may be an important explanation of the association between aneurysm formation and reduced respiratory function. Further studies are required to test this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16520158     DOI: 10.1016/j.jvs.2005.11.018

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  16 in total

Review 1.  Circulating markers of abdominal aortic aneurysm presence and progression.

Authors:  Jonathan Golledge; Philip S Tsao; Ronald L Dalman; Paul E Norman
Journal:  Circulation       Date:  2008-12-02       Impact factor: 29.690

2.  Prospective study of lung function and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study.

Authors:  Yasuhiko Kubota; Aaron R Folsom; Kunihiro Matsushita; David Couper; Weihong Tang
Journal:  Atherosclerosis       Date:  2017-10-13       Impact factor: 5.162

3.  Dynamic Changes in Coagulation Function in Patients With Pneumonia Under Admission and Non-admission Treatment.

Authors:  Jiasheng Xu; Yongmei Zhang; Yiran Li; Kaili Liao; Xiong Zeng; Xiande Zeng; Rui Meng; Weimin Zhou; Kai Wang; Yuanqi Gong; Fuzhou Hua; Jianjun Xu; Jiehua Qiu
Journal:  Front Med (Lausanne)       Date:  2021-05-24

Review 4.  Novel aspects of the pathogenesis of aneurysms of the abdominal aorta in humans.

Authors:  Jean-Baptiste Michel; José-Luis Martin-Ventura; Jesus Egido; Natzi Sakalihasan; Vladislav Treska; Jes Lindholt; Eric Allaire; Unnur Thorsteinsdottir; Gillian Cockerill; Jesper Swedenborg
Journal:  Cardiovasc Res       Date:  2010-10-30       Impact factor: 10.787

5.  Fibrinogen as a potential biomarker for clinical phenotype in patients with chronic obstructive pulmonary disease.

Authors:  Tae Hoon Kim; Dong Kyu Oh; Yeon-Mok Oh; Sei Won Lee; Sang Do Lee; Jae Seung Lee
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 3.005

6.  Screening of COPD patients for abdominal aortic aneurysm.

Authors:  Ingo H Flessenkaemper; Robert Loddenkemper; Stephanie Roll; Kathrin Enke-Melzer; Henrik Wurps; Torsten T Bauer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-06-10

7.  Remote effects of lower limb ischemia-reperfusion: impaired lung, unchanged liver, and stimulated kidney oxidative capacities.

Authors:  Z Mansour; A L Charles; M Kindo; J Pottecher; T N Chamaraux-Tran; A Lejay; J Zoll; J P Mazzucotelli; B Geny
Journal:  Biomed Res Int       Date:  2014-08-10       Impact factor: 3.411

8.  Association analysis of genetic polymorphisms of factor V, factor VII and fibrinogen β chain genes with human abdominal aortic aneurysm.

Authors:  Katarzyna Oszajca; Konrad Wroński; Grażyna Janiszewska; Małgorzata Bieńkiewicz; Michał Panek; Jacek Bartkowiak; Janusz Szemraj
Journal:  Exp Ther Med       Date:  2012-06-12       Impact factor: 2.447

Review 9.  Interleukin-6 receptor pathways in abdominal aortic aneurysm.

Authors:  Seamus C Harrison; Andrew J P Smith; Gregory T Jones; Daniel I Swerdlow; Riaz Rampuri; Matthew J Bown; Lasse Folkersen; Annette F Baas; Gert Jan de Borst; Jan D Blankensteijn; Jacqueline F Price; Yolanda van der Graaf; Stela McLachlan; Obi Agu; Albert Hofman; Andre G Uitterlinden; Anders Franco-Cereceda; Ynte M Ruigrok; F N van't Hof; Janet T Powell; Andre M van Rij; Juan P Casas; Per Eriksson; Michael V Holmes; Folkert W Asselbergs; Aroon D Hingorani; Steve E Humphries
Journal:  Eur Heart J       Date:  2012-10-30       Impact factor: 29.983

Review 10.  Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease.

Authors:  Annelyse Duvoix; Jenny Dickens; Imran Haq; David Mannino; Bruce Miller; Ruth Tal-Singer; David A Lomas
Journal:  Thorax       Date:  2012-06-28       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.